EHA 2021 update in hematology - Sunday 13th June 18. 00- 19:30 CEST
This introductory video outlines learning goals of the session, and some key studies presented.
In this session, BTK-related pathways and the rationale for targeting BTK as a treatment option in patients with indolent B- cell lymphomas will be thoroughly discussed.
Outcomes of the phase 3 MAGNOLIA study of zanubrutinib in relapsed/refractory marginal zone lymphoma (MZL) will be presented, along with results form a phase 2 study of zanubrutinib in patients with intolerability to first line BTK inhibitors.